Novi Zan\'s announcement on the departure of core technical staff
Notice from Novartis on the voluntary disclosure of fully-owned subsidiary's acquisition of medical instruments registration certificate.
Notice of Resolutions of the 2023 Annual Shareholders' Meeting of NuoWeiZan
Legal Opinion of Tianyuan Law Firm regarding the 2023 Shareholders' Meeting of Nanjing Novozymes Biotechnology Co., Ltd. in Peking
2023 Annual General Meeting of Shareholders Meeting Materials
Novi Zane's Notice on Convening the 2023 Annual General Meeting of Shareholders
Novi Zan's Announcement on Voluntary Disclosure of Wholly-Owned Subsidiaries Signed Cooperation Agreements
2024 “Improve Quality, Increase Efficiency, and Focus on Return” Special Action Plan
Novi Zan's announcement on preparation for impairment of accrued assets and write-off of assets for 2023
Novi Zan's announcement on the extension of fund-raising investment projects
Novi Zan's announcement on revisions to the “Articles of Association” and some internal governance systems
“Articles of Association” (revised in April 2024)
Rules of Procedure for Board of Directors (Revised April 2024)
“Rules of Work for the Audit Committee of the Board of Directors” (revised in April 2024)
“Board Strategy and ESG Committee Work Rules” (April 2024)
“Rules of Work of the Remuneration and Assessment Committee of the Board of Directors” (revised in April 2024)
“Rules of Work of the Nomination Committee of the Board of Directors” (revised in April 2024)
Novi Zan's Announcement on the 2024 Remuneration Plan for Directors, Supervisors and Senior Executives
Novi Zan's announcement on the use of temporarily idle funds to purchase wealth management products
Novi Zan's announcement on adjustments to the company's organizational structure
No Data